Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05034536 | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | active not recruiting | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01644591 | Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases | active not recruiting | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04572451 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma |
| active not recruiting |
| Phase 1 |
| 50 |
| Yana NajjarOTHER |
| 1 |
| Aug 20, 2026 |
| clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07160335 | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | active not recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT03646617 | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma(RadVax) | active not recruiting | Phase 2 | 62 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06146920 | Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation | active not recruiting | N/A | 39 | Massachusetts General HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT00338377 | Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | active not recruiting | Phase 2 | 1,230 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01989585 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | active not recruiting | Phase 1 / Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04588662 | A Prospective Natural History Study in Uveal Melanoma | active not recruiting | — | 122 | Columbia UniversityOTHER | 5 | Aug 11, 2026 | clinicaltrials |
| NCT02231775 | Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | active not recruiting | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06237881 | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04099251 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma(CheckMate76K) | active not recruiting | Phase 3 | 790 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 7, 2026 | clinicaltrials |
| NCT01979523 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 3 | Aug 6, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT00591500 | A Model for Genetic Susceptibility: Melanoma | active not recruiting | — | 4,082 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04356729 | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 30 | F. Stephen Hodi, MDOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03698019 | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | active not recruiting | Phase 2 | 313 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05068102 | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | active not recruiting | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma(CoMpass) | active not recruiting | Phase 3 | 108 | Aura BiosciencesINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT04996823 | Axitinib + Ipilimumab in Advanced Melanoma | active not recruiting | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT01587352 | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | active not recruiting | Phase 2 | 87 | Vyriad, Inc.INDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05015816 | MoleGazer Development Feasibility Study | active not recruiting | N/A | 374 | Oxford University Hospitals NHS TrustOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02775851 | Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery | active not recruiting | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04478318 | Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma | active not recruiting | N/A | 180 | University of California, DavisOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05608291 | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | active not recruiting | Phase 3 | 1,564 | Regeneron PharmaceuticalsINDUSTRY | 22 | Jul 6, 2026 | clinicaltrials |
| NCT04835805 | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | active not recruiting | Phase 1 | 65 | Genentech, Inc.INDUSTRY | 5 | Jul 1, 2026 | clinicaltrials |
| NCT03311308 | A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | active not recruiting | Phase 1 | 23 | Yana NajjarOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00539591 | Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma | active not recruiting | Phase 2 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03175432 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03285230 | The French E3N Prospective Cohort Study(E3N) | active not recruiting | — | 100,000 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT06416085 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | active not recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04722575 | Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma(NEO-TIM) | active not recruiting | Phase 2 | 95 | Fondazione Melanoma OnlusOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04305145 | Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | active not recruiting | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials